Last reviewed · How we verify
Low-titer anti-influenza plasma
Low-titer anti-influenza plasma is a Convalescent plasma Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for Hospitalized patients with acute influenza infection.
Low-titer anti-influenza plasma provides passive immunotherapy by transferring antibodies from donors with prior influenza exposure to neutralize circulating influenza virus in infected patients.
Low-titer anti-influenza plasma provides passive immunotherapy by transferring antibodies from donors with prior influenza exposure to neutralize circulating influenza virus in infected patients. Used for Hospitalized patients with acute influenza infection.
At a glance
| Generic name | Low-titer anti-influenza plasma |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Convalescent plasma |
| Target | Influenza virus surface antigens (hemagglutinin, neuraminidase) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This convalescent plasma product contains low concentrations of anti-influenza antibodies harvested from donors who have recovered from influenza infection. When transfused into acutely infected patients, these antibodies bind to viral surface antigens and facilitate viral neutralization and clearance. The approach leverages passive immunity to reduce viral load and potentially ameliorate disease severity in hospitalized influenza patients.
Approved indications
- Hospitalized patients with acute influenza infection
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Volume overload
- Transfusion-transmitted infection
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-titer anti-influenza plasma CI brief — competitive landscape report
- Low-titer anti-influenza plasma updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Low-titer anti-influenza plasma
What is Low-titer anti-influenza plasma?
How does Low-titer anti-influenza plasma work?
What is Low-titer anti-influenza plasma used for?
Who makes Low-titer anti-influenza plasma?
What drug class is Low-titer anti-influenza plasma in?
What development phase is Low-titer anti-influenza plasma in?
What are the side effects of Low-titer anti-influenza plasma?
What does Low-titer anti-influenza plasma target?
Related
- Drug class: All Convalescent plasma drugs
- Target: All drugs targeting Influenza virus surface antigens (hemagglutinin, neuraminidase)
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Hospitalized patients with acute influenza infection
- Compare: Low-titer anti-influenza plasma vs similar drugs
- Pricing: Low-titer anti-influenza plasma cost, discount & access